Beauty's 'Great Undoing' Drives M&A
The beauty industry's M&A focus is shifting to clinical, science-backed brands as conglomerates like L'Oréal respond to the "Great Cosmetic Undoing" — a consumer trend away from maximalist routines. A recent *Vanity Fair* analysis highlights this portfolio rebalancing, while industry experts note that acquirers are aggressively targeting derm-backed and wellness labels to secure higher margins.
The average beauty M&A deal price has dropped from €400 million in 2022 to €160 million, as investors pivot from large-scale acquisitions to smaller, high-growth "growth acceleration" investments. Despite a 6.7% dip in deal volume in 2025, beauty M&A remains resilient compared to the broader consumer industry's 24.2% decline, with target companies fetching premium prices averaging 14.9x EV/EBITDA. L'Oréal exemplifies this strategic shift, acquiring a majority stake in the British clinical skincare brand Medik8 for a reported €1 billion. Founded by a scientist, Medik8 is projected to hit $115 million in 2025 sales and gives L'Oréal a stronger foothold in the derm-meets-luxury space, complementing prior acquisitions like Skinbetter Science and SkinCeuticals. This realignment comes as hype-driven brands falter. Pat McGrath Labs, once valued at over $1 billion, filed for Chapter 11 bankruptcy, joining a growing list of closures including Cover FX and Flower Beauty. This industry fracture highlights a move away from businesses built for buzz and quick exits toward those with defensible science and long-term value. Other conglomerates are also shedding assets that don't fit the new clinical focus. Unilever is winding down Ren Clean Skincare after failing to find a buyer, and LVMH is reportedly exploring the sale of Make Up For Ever, which has been loss-making for eight consecutive years. This contrasts with proactive acquisitions like E.l.f. Beauty's $1 billion purchase of Hailey Bieber's Rhode Skin. The consumer is driving this change, reallocating spending from brands that rely on prestige positioning to those demonstrating value with evidence. While luxury department stores are contracting, the off-price retail market is growing at an 8% compound annual growth rate, with non-luxury brands now holding 7 of the top 20 hottest brand spots globally, up from just 2 in 2022. Industry insiders are now watching a new class of potential targets that fit the science-first profile. A recent Kearney report identified brands like Makeup By Mario, Augustinus Bader, Kosas, and Versed as prime acquisition candidates. Skincare and injectables are the most sought-after M&A categories. The focus has expanded beyond just brands to the ingredient platforms themselves. L'Oréal has invested in microbiome research by acquiring Danish firm Lactobio and committed $383 million to an AI-powered formulation tech hub in India, signaling that future M&A will target upstream capabilities in biotech and R&D.
